phenotypic marker expression.
Cell-penetrating peptides (CPPs) facilitate efficient biomolecule delivery with low immunogenicity and cytotoxicity, making them ideal for in vivo drug delivery. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a ligand of the epidermal growth factor receptor (EGFR), is overexpre...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry
2025-06-01
|
| Series: | Biotechnologia Acta |
| Subjects: | |
| Online Access: | https://biotechnology.kiev.ua/images/BTA/2025/3_2025/_Gamaliia_3_2025.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849412982549774336 |
|---|---|
| author | I.I. Gamaliia A.A. Siromolot D.V. Kolybo |
| author_facet | I.I. Gamaliia A.A. Siromolot D.V. Kolybo |
| author_sort | I.I. Gamaliia |
| collection | DOAJ |
| description | Cell-penetrating peptides (CPPs) facilitate efficient biomolecule delivery with low immunogenicity and cytotoxicity, making them ideal for in vivo drug delivery. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a ligand of the epidermal growth factor receptor (EGFR), is overexpressed in tumors and can promote angiogenesis. Doxorubicin (DOX), a chemotherapeutic, treats various cancers but has limited use with HB-EGF as a carrier.
Aim. In this study we focused on the HB-EGF’s potential in enhancing DOX delivery and antitumor effects.
Methods. Recombinant sHB-EGF was expressed in E. coli, purified by IMAC, and loaded with DOX with further dialysis of the complex from unbound antibiotics. Binding to cell surfaces (A431, 3T3, Vero), as well as ROS production using DCFH-DA, were analyzed by flow cytometry. Cell viability was assessed with MTT assays after 48 h.
Results: sHB-EGF fluorescent derivatives effectively bound to A431 cells, enhancing DOX delivery to squamous-cell carcinoma and significantly reducing cell viability.
Conclusions: HB-EGF efficiently delivers DOX into cells, suggesting its potential as a targeted drug carrier for EGFR/ErbB-1 overexpressed cancers. |
| format | Article |
| id | doaj-art-b89ef527ce7d400898f9cf9cf6df9592 |
| institution | Kabale University |
| issn | 2410-7751 2410-776X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry |
| record_format | Article |
| series | Biotechnologia Acta |
| spelling | doaj-art-b89ef527ce7d400898f9cf9cf6df95922025-08-20T03:34:17ZengNational Academy of Sciences of Ukraine, Palladin Institute of BiochemistryBiotechnologia Acta2410-77512410-776X2025-06-01183394410.15407/biotech18.03.039phenotypic marker expression.I.I. Gamaliia0A.A. Siromolot1D.V. Kolybo21 Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Ukraine 2 Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kyiv1 Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Ukraine 2 Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kyiv Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, KyivCell-penetrating peptides (CPPs) facilitate efficient biomolecule delivery with low immunogenicity and cytotoxicity, making them ideal for in vivo drug delivery. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a ligand of the epidermal growth factor receptor (EGFR), is overexpressed in tumors and can promote angiogenesis. Doxorubicin (DOX), a chemotherapeutic, treats various cancers but has limited use with HB-EGF as a carrier. Aim. In this study we focused on the HB-EGF’s potential in enhancing DOX delivery and antitumor effects. Methods. Recombinant sHB-EGF was expressed in E. coli, purified by IMAC, and loaded with DOX with further dialysis of the complex from unbound antibiotics. Binding to cell surfaces (A431, 3T3, Vero), as well as ROS production using DCFH-DA, were analyzed by flow cytometry. Cell viability was assessed with MTT assays after 48 h. Results: sHB-EGF fluorescent derivatives effectively bound to A431 cells, enhancing DOX delivery to squamous-cell carcinoma and significantly reducing cell viability. Conclusions: HB-EGF efficiently delivers DOX into cells, suggesting its potential as a targeted drug carrier for EGFR/ErbB-1 overexpressed cancers.https://biotechnology.kiev.ua/images/BTA/2025/3_2025/_Gamaliia_3_2025.pdftargeted drug deliveryshb-egfdoxorubicinegfrcancer therapy. |
| spellingShingle | I.I. Gamaliia A.A. Siromolot D.V. Kolybo phenotypic marker expression. Biotechnologia Acta targeted drug delivery shb-egf doxorubicin egfr cancer therapy. |
| title | phenotypic marker expression. |
| title_full | phenotypic marker expression. |
| title_fullStr | phenotypic marker expression. |
| title_full_unstemmed | phenotypic marker expression. |
| title_short | phenotypic marker expression. |
| title_sort | phenotypic marker expression |
| topic | targeted drug delivery shb-egf doxorubicin egfr cancer therapy. |
| url | https://biotechnology.kiev.ua/images/BTA/2025/3_2025/_Gamaliia_3_2025.pdf |
| work_keys_str_mv | AT iigamaliia phenotypicmarkerexpression AT aasiromolot phenotypicmarkerexpression AT dvkolybo phenotypicmarkerexpression |